2011 · 17 citations · 9 references
PharmacyPharmaceutical AnalysisPharmaceuticsAnalytical ChemistryChromatographic AnalysisMass Spectrometric AnalysisAnalytical ChromatographyInhalation Dosage FormsSpectroscopic Analysis Of PharmaceuticalsChronic Obstructive Pulmonary Disease AssessmentPhosphate Buffer SystemSimultaneous Equation EstimationSimultaneous Equation SystemsUv-visible Quantitative Analysis
Fixed dose combination containing salmeterol xinafoate and fluticasone propionate is widely used in the treatment of bronchial asthma and chronic obstructive pulmonary diseases. In this research we aimed to develop a simple, accurate, precise, sensitive, selective and economical spectrophotometric method that requires no prior separation for the simultaneous estimation of salmeterol xinafoate and fluticasone propionate in capsule dosage form. The estimation was based upon the simultaneous equation method which was carried out at the wavelength of 214 nm and 246 nm for salmeterol xinafoate and fluticasone propionate respectively. Phosphate buffer (pH 7.4): Ethanol (95%) (90:10) was used as solvent. The linearity lies between 5 to 14 µg/ml for salmeterol xinafoate and 2 to 14 µg/ml for fluticasone propionate. The mean results of estimation in capsule were 99.82±0.11% & 99.89±0.05% of the label claim for salmeterol and fluticasone respectively. The accuracy and precision of the method were determined and validated according to ICH guidelines. The method had good reproducibility and recovery with % RSD less than 1. Thus the proposed method can be successfully applied for simultaneous determination of salmeterol xinafoate and fluticasone propionate in routine analysis work.
9
The Pharmacological Basis of Therapeutics
American Journal of Health-System Pharmacy · 1976 · 8.2K citations
Darragh Murnane, Gary P. Martin, C Marriott · Journal of Pharmaceutical and Biomedical Analysis · 2005 · 56 citations
Daniele Di Corcia, V. Morra, Marco Pazzi et al. · Biomedical Chromatography · 2009 · 46 citations